Mehret Birru Talabi1, Megan E B Clowse2, Susan J Blalock3, Larry Moreland1, Nalyn Siripong1, Sonya Borrero4. 1. University of Pittsburgh, Pittsburgh, Pennsylvania. 2. Duke University Medical Center, Durham, North Carolina. 3. University of North Carolina Eshelman School of Pharmacy, Chapel Hill. 4. University of Pittsburgh and Center for Health Equity Research and Promotion, Veterans Administration Pittsburgh Healthcare System, Pittsburgh, Pennsylvania.
Abstract
OBJECTIVE: To determine contraception use among a cohort of reproductive-age women (ages 18-50 years) with rheumatic diseases. METHODS: We conducted a study of administrative data from a single, large medical center between the years 2013 and 2014. Women who had 1 of 21 possible rheumatic disease diagnoses and had at least 2 outpatient rheumatology visits were included in this analysis. We used logistic regression analyses to evaluate adjusted associations between the use of prescription contraception, use of potentially fetotoxic medications, and visits with rheumatologists, primary care providers, and gynecologists. RESULTS: Of 2,455 women in this sample, 32.1% received any prescription contraception, and 7.9% of women used highly effective prescription methods (intrauterine devices, implants, and surgical sterilization). More than 70% of women took ≥1 type of fetotoxic medication during the 2-year study timeframe. Fetotoxic medication use was not associated with overall use of prescription contraception, but was associated with the use of highly effective contraceptive methods (adjusted odds ratio [OR] 2.26 [95% confidence interval (95% CI) 1.44-3.54]). Women who saw gynecologists or primary care providers were more likely to use prescription contraception overall (adjusted OR 3.35 [95% CI 2.77-4.05] and 1.43 [95% CI 1.18-1.73], respectively). Women who saw gynecologists were more likely to use highly versus moderately effective contraceptive methods (adjusted OR 2.35 [95% CI 1.41-3.94]). Rheumatology visits were not associated with use of prescription contraception in any models. CONCLUSION: This is the largest study to date to describe contraceptive use among reproductive-age women with rheumatic diseases, and the findings reveal low use of prescription contraception. Urgent efforts are needed to improve contraceptive care and access for some women with rheumatic diseases.
OBJECTIVE: To determine contraception use among a cohort of reproductive-age women (ages 18-50 years) with rheumatic diseases. METHODS: We conducted a study of administrative data from a single, large medical center between the years 2013 and 2014. Women who had 1 of 21 possible rheumatic disease diagnoses and had at least 2 outpatientrheumatology visits were included in this analysis. We used logistic regression analyses to evaluate adjusted associations between the use of prescription contraception, use of potentially fetotoxic medications, and visits with rheumatologists, primary care providers, and gynecologists. RESULTS: Of 2,455 women in this sample, 32.1% received any prescription contraception, and 7.9% of women used highly effective prescription methods (intrauterine devices, implants, and surgical sterilization). More than 70% of women took ≥1 type of fetotoxic medication during the 2-year study timeframe. Fetotoxic medication use was not associated with overall use of prescription contraception, but was associated with the use of highly effective contraceptive methods (adjusted odds ratio [OR] 2.26 [95% confidence interval (95% CI) 1.44-3.54]). Women who saw gynecologists or primary care providers were more likely to use prescription contraception overall (adjusted OR 3.35 [95% CI 2.77-4.05] and 1.43 [95% CI 1.18-1.73], respectively). Women who saw gynecologists were more likely to use highly versus moderately effective contraceptive methods (adjusted OR 2.35 [95% CI 1.41-3.94]). Rheumatology visits were not associated with use of prescription contraception in any models. CONCLUSION: This is the largest study to date to describe contraceptive use among reproductive-age women with rheumatic diseases, and the findings reveal low use of prescription contraception. Urgent efforts are needed to improve contraceptive care and access for some women with rheumatic diseases.
Authors: Christina D Chambers; Diana L Johnson; Luther K Robinson; Stephen R Braddock; Ronghui Xu; Janina Lopez-Jimenez; Nicole Mirrasoul; Elizabeth Salas; Yunjun J Luo; Shelia Jin; Kenneth Lyons Jones Journal: Arthritis Rheum Date: 2010-05
Authors: Eleanor Bimla Schwarz; Debbie A Postlethwaite; Yun-Yi Hung; Mary Anne Armstrong Journal: Ann Intern Med Date: 2007-09-18 Impact factor: 25.391
Authors: Mehret Birru Talabi; Megan E B Clowse; Susan J Blalock; Megan Hamm; Sonya Borrero Journal: Arthritis Care Res (Hoboken) Date: 2020-03 Impact factor: 4.794
Authors: Megan E B Clowse; Jing Li; Mehret Birru Talabi; Amanda M Eudy; Gabriela Schmajuk Journal: Arthritis Care Res (Hoboken) Date: 2021-10-08 Impact factor: 4.794
Authors: David L Leverenz; Amanda M Eudy; Malithi Jayasundara; Tayseer Haroun; Gary McDaniel; W Benjamin Nowell; Jeffrey R Curtis; Rachelle Crow-Hercher; Whitney White; Seth Ginsberg; Megan E B Clowse Journal: Clin Rheumatol Date: 2019-01-16 Impact factor: 2.980
Authors: Jessica N Williams; Chang Xu; Karen H Costenbader; Bonnie L Bermas; Lydia E Pace; Candace H Feldman Journal: Arthritis Care Res (Hoboken) Date: 2021-09-02 Impact factor: 5.178
Authors: Tierney Wolgemuth; Olivia M Stransky; Alaina Chodoff; Traci M Kazmerski; Megan E B Clowse; Mehret Birru Talabi Journal: Arthritis Care Res (Hoboken) Date: 2021-07-14 Impact factor: 5.178